# A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

> **NCT05176951** · PHASE2 · COMPLETED · sponsor: **Insmed Incorporated** · enrollment: 39 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Treprostinil Palmitil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05176951
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-22
- **Primary completion:** 2024-03-14
- **Final completion:** 2024-03-14
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05176951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05176951, "A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05176951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*